Capricor Eyes RMAT Designation Based On Interim Phase II Data

Apr 25 2017

• By Mandy Jackson

Listen to this article

Capricor reported positive interim Phase I/II results for its cell therapy designed to treat cardiomyopathy in DMD patients and said it plans to seek regenerative medicine advanced technology, breakthrough or both designations from the US FDA.

microscope

Capricor Therapeutics Inc. is considering whether to seek the US FDA's Regenerative Medicine Advanced Technology (RMAT) designation, a breakthrough therapy designation or both for CAP-1002 (allogeneic cardiosphere-derived cells) in the treatment of Duchenne muscular dystrophy (DMD) based on positive interim results from the ongoing 12-month Phase I/II HOPE clinical trial.

Los Angeles-based Capricor designed CAP-1002 to improve cardiomyopathy, which increases as DMD progresses, but in addition to reducing cardiac scarring,...

More from Cell & Gene Therapies

test carousel-PINKSHEET
Oct 14 2025
• By Saba Afreen
test carousel-test
Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone
Aug 16 2025
• By Sue Sutter
In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.
Link test - Akash
Oct 30 2024
Testing all options - Akash
Oct 01 2024
• By Akash
This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged
Sep 27 2024
• By Sue Sutter
Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.
test
Sep 25 2024
• By Sabbah and Saba Afreen
test
Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST
Sep 25 2024
• By Sue Sutter
Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.